Increase in mammographic breast density associated with the use of domperidone

Breast Journal

Volumn 10, Issue 3, 2004, Pages 256-258

  Harvey, Jennifer A ^a   Cowan III, James H ^a   LoRusso, Alexander P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOMPERIDONE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PROPRANOLOL;

ADULT; AMENORRHEA; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EXAMINATION; BREAST TENDERNESS; CASE REPORT; CELL PROLIFERATION; CLINICAL FEATURE; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GASTROESOPHAGEAL REFLUX; GYNECOMASTIA; HUMAN; HUMAN TISSUE; IRRITABLE COLON; LACTATION; MAMMARY GLAND; MAMMOGRAPHY; MIGRAINE; PREMENOPAUSE; STOMACH PARESIS;

ANTIEMETICS; BREAST; BREAST DISEASES; BREAST NEOPLASMS; DOMPERIDONE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; TIME FACTORS;

EID: 2642517878     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21441.x     Document Type: Article

References (14)

1. Tohno E, Cosgrove DO, Sloane JP. Ultrasound Diagnosis of Breast Diseases. New York: Churchill Livingstone, 1996.
2. Motilium package insert. Janssen Pharmaceutica (Pty) Ltd., South Africa, 1990.
3. daSilva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo controlled trial. Can Med Assoc J 2001;164:17-21.
4. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-34.
5. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000;19:1072-76.
6. Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002;59:1147-54.
7. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998;209:511-18.
8. Byrne C, Schairer C, Wolfe J, etal. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-29.
9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
10. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-20.
11. Chow CK, Venson D, Jones EC, et al. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-21.
12. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-56.
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
14. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-7.